<DOC>
	<DOCNO>NCT00272285</DOCNO>
	<brief_summary>The purpose study compare efficacy safety ramosetron plus dexamethasone injection granisetron plus dexamethasone injection prevention chemotherapy-induced vomit nausea .</brief_summary>
	<brief_title>A Study Ramosetron Plus DX , Dexamethasone , Compared Granisetron Plus DX Prevention Vomiting Nausea</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Granisetron</mesh_term>
	<mesh_term>Ramosetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Subject age 2074 year old ( inclusive ) either sex Cancer subject schedule receive designate chemotherapy program Subject without symptom vomit least one week dose trial medication Subject ECOG performance status scale great 2 Subject sign write informed consent form Subject receive radiotherapy abdomen pelvis within 4 week enter study Subject receive designated chemotherapy program within 6 month enter study Subject know heart failure myocardial infraction laboratory abnormality screen Subject know concurrent disease may cause vomit Subject take medication could influence outcome study within 3 day enter study Subject history allergy intolerance ramosetron , granisetron dexamethasone Female subject pregnant breastfeeding Subject life expectancy le 3 month Subject participate investigational drug trial within 1 month enter study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Serotonin antagonist</keyword>
	<keyword>Randomized control trial</keyword>
	<keyword>Combination drug therapy</keyword>
	<keyword>Double-blind method</keyword>
</DOC>